Nikon, Verily to develop machine learning-enabled solutions for diabetes-related eye disease

Nikon Corp and its subsidiary Optos Plc have announced a strategic alliance with Verily Life Sciences LLC in the field of machine learning-enabled retinal imaging. The companies will collaborate on creating technology and solutions for enhanced screening of diabetic retinopathy and diabetic macular edema by diabetes-treating physicians and others to assist in efficient referral of patients to eyecare specialists, and provide these specialists with assisted reading programs for easier diagnosis of disease.

Diabetic retinopathy and diabetic macular edema are leading causes of blindness among adults around the world, and improved access and screening rates can prevent disease progression and blindness. According to the World Health Organization (WHO), the number of diabetic patients is increasing rapidly in many parts of the world, especially in low to middle income countries. As a result, the number of patients with vision impairment and the need to monitor these patients is also expected to grow.

Through an exclusive collaboration in numerous geographies, Nikon (including its subsidiary Optos) and Verily will co-develop solutions for the earlier detection of diabetic retinopathy and diabetic macular edema. The partnership will combine Nikon's leadership in optical engineering and precision manufacturing, its proprietary ultra-widefield technology and strong commercial presence among eyecare specialists, and Verily's machine learning technology. Together, Nikon and Verily will work to provide innovative medical solutions to assist physicians, and address a broad population of diabetic patients.

About diabetic retinopathy and diabetic macular edema

Diabetic retinopathy is caused by progressive damage to the blood vessels of the retina. It is the most common eye disease among people with diabetes, and a leading cause of visual impairment and blindness among working-age adults. Without appropriate intervention, the disease can silently progress from early stage diabetic retinopathy when many patients are asymptomatic, to more severe stages when patients begin to experience vision loss, which often cannot be reversed.

Diabetic macular edema is a complication of diabetic retinopathy, caused by fluid accumulation in the eye. Early detection and intervention can significantly reduce the risk of permanent vision loss from these diseases, so effective screening of patients is crucial.

© Japan Today